Motacabtagene lurevgedleucel

N/A

Report date: 2025/01/09 20:00:05

Base Information

Drug NameMotacabtagene lurevgedleucel

Drug Alias NameCTX-120

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-BCMA

TargetsB-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesAustralia +[4]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCrispr Therapeutics Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCrispr Therapeutics Ag

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A